Skip to main content
. 2017 Feb;102(2):373–380. doi: 10.3324/haematol.2016.144964

Figure 4.

Figure 4.

KDM6B inhibition by GSK-J4 affects BCR-driven survival pathways. (A) Analysis of B-cell/BCR signaling using western blot for phosphorylated/active forms of pBTKTYR223, pPLCγTYR759, and pCD79ATYR182. (B) Sensitivity of BCR wild type (WT) and BCR-knockout (KO) (generated with Crisper-Cas9 KO constructs) SU-DHL-6 cells to treatment of GSK-J4 was analyzed as change in absolute number of BCR WT and BCR-KO cells (normalized with equal numbers of beads) 24 h after treatment. (C) Effect of GSK-J4 on survival pathway proteins such as BCL6 in SU-DHL-6 cells analyzed by western blots. (D) KDM6B knockdown SU-DHL-6 cells generated using siRNA against KDM6B were used to analyze specific inhibition of BCL6 by western blot. (E) Effect of BCR knockdown on BCL6 levels in cell lines. BCR-KO was achieved using the Crisper-cas9 method.